16.02.2018 | BPS Satellite Meeting: Drug Discovery for Ion Channels XVII
Conference Venue: Moscone Center, Esplanade Room 153, San Francisco, USA
Go to the Conference website here.
We are proud to be sponsor of the Meeting.
Meet Niels Fertig, Andrea Brüggemann, Frank Henrichsen, Michael George, Maria Barthmes, Claudia Haarmann from Nanion headquarters in Munich and Rodolfo Haedo, Corina Bot, James Costantin, George Okeyo and Tim Strassmaier from Nanion Inc. USA.
Ion channels are an important class of therapeutic drug targets, and mutations in ion channel genes are found to be responsible for an increasing number of diseases. While conventional electrophysiological techniques permit the most detailed and direct study of ion channel function, they are limited due to the manual nature of the method and their low throughput. Because of this, ion channels remain an underrepresented target class for drug discovery. The advent of higher throughput automated electrophysiology systems has begun to change the face of ion channel drug discovery. Since the inaugural “Drug Discovery for Ion Channels” satellite meeting, there have been many advances in ion channel drug discovery including new instrumentation and techniques. This year’s meeting will highlight presentations from users of automated electrophysiology instrumentation as well as other speakers in the field of ion channel drug discovery, including several academic speakers.
- 8:00 AM - 8:30 AM Registration and Coffee
- 8:30 AM - 8:45 AM Thais Johansen, Sophion Bioscience
Welcome and Opening Remarks
- 8:45 AM - 9:30 AM Keynote Speaker: David Julius, University of California, San Francisco
Natural products as probes of the pain pathway: from physiology to atomic structure
- 9:30 AM - 10:00 AM Stephan Pless, University of Copenhagen, Denmark
High-throughput validation of incorporation of unnatural amino acids into an ion channel
- 10:00 AM - 10:30 AM Damian Bell, Iontas, United Kingdom
KnotBodiesTM: a new generation of ion channel therapeutic biologics created by fusing knottin toxins into antibodies
- 10:30 AM - 11:00 AM Coffee Break
- 11:00 AM - 11:30 AM Julie Klint, H. Lundbeck A/S, Denmark
Finding Nav1.1 activators – development and validation of a HTS suitable assay
- 11:30 AM - 12:00 PM Charles Cohen, Xenon Pharma, Canada
A Novel Pain and Target Engagement Assay for hNaV1.7: efficacy in inflammatory and neuropathic pain models correlates with residence time for inhibition of
- 12:00 PM - 12:30 PM Jun Chen, Genentech
Sodium channel activators: from mechanisms to drug binding sites
- 12:30 PM - 1:30 PM Lunch
- 1:30 PM - 2:00 PM Kris Kahlig, NeuroCardPM Consulting
Benchmarking Eleclazine: Biophysical characterization of a cardiac Late INa inhibitor
- 2:00 PM – 2:30 PM Saverio Gentile, Loyola University Chicago
A Channelopathy Called Cancer: From Discovering Novel Roles of Ion Channels to Designing Novel Precision Cancer Medicine
- 2:30 PM - 3:00 PM Jen Q. Pan, Broad Institute
Functional Annotation of ion channels implicated by human genetics with 384 channel APC
- 3:00 PM - 3:30 PM Coffee Break
- 3:30 PM – 3:55 PM Stephen Smith, Photoswitch Biosciences Inc.
A next generation optical plate reader for capturing data at the speed of membrane biology
- 3:55 PM - 4:20 PM Robert Bowser, Gregory W. Fulton ALS Research Center and Neuromuscular Research Center; Barrow Neurological Institute, St. Joseph’s Hospital and Medical Center
Targeting the Cu transporter ATP7A for treatment of amyotrophic lateral sclerosis (ALS)
- 4:20 PM - 4:45 PM Thomas Licher, Sanofi-Aventis
Pharmacological characterization of an amino acid transporter and his bacterial homologue – a case study using solid supported membrane technology
- 4:45 PM - 5:10 PM Alex Savchenko, Nanotools Bioscience
Microplate-based dynamic optical stimulation of human iPSC-derived cardiomyocytes for all-optical cardiotoxicity assays
- 5:10 PM Chris Mathes, Icagen Inc.
Pre-Registration Now Open (Deadline: January 15, 2018)